IL274676A - הרכב לקשירת אנטיגן דו-ספציפי - Google Patents

הרכב לקשירת אנטיגן דו-ספציפי

Info

Publication number
IL274676A
IL274676A IL274676A IL27467620A IL274676A IL 274676 A IL274676 A IL 274676A IL 274676 A IL274676 A IL 274676A IL 27467620 A IL27467620 A IL 27467620A IL 274676 A IL274676 A IL 274676A
Authority
IL
Israel
Prior art keywords
antigen binding
bispecific antigen
binding construct
construct
bispecific
Prior art date
Application number
IL274676A
Other languages
English (en)
Inventor
Christophe Blanchetot
Der Woning Sebastian Van
Original Assignee
Argenx Bvba
Christophe Blanchetot
Der Woning Sebastian Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba, Christophe Blanchetot, Der Woning Sebastian Van filed Critical Argenx Bvba
Publication of IL274676A publication Critical patent/IL274676A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL274676A 2017-12-22 2020-05-14 הרכב לקשירת אנטיגן דו-ספציפי IL274676A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609523P 2017-12-22 2017-12-22
PCT/EP2018/086755 WO2019122409A1 (en) 2017-12-22 2018-12-21 Bispecific antigen binding construct

Publications (1)

Publication Number Publication Date
IL274676A true IL274676A (he) 2020-06-30

Family

ID=64959348

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274676A IL274676A (he) 2017-12-22 2020-05-14 הרכב לקשירת אנטיגן דו-ספציפי

Country Status (8)

Country Link
US (1) US20190218310A1 (he)
EP (1) EP3728328A1 (he)
JP (2) JP2021506310A (he)
CN (1) CN111448217A (he)
AU (1) AU2018387829A1 (he)
CA (1) CA3079793A1 (he)
IL (1) IL274676A (he)
WO (1) WO2019122409A1 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090687A4 (en) * 2020-01-19 2024-02-21 Nanjing Genscript Biotech Co Ltd MULTI-SPECIFIC ANTI-CLAUDINE-18.2 CONSTRUCTS AND THEIR USES
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
MX2011010158A (es) 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
PL2975051T3 (pl) 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
GB2476681B (en) * 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
US10689447B2 (en) * 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
US9815909B2 (en) 2012-03-13 2017-11-14 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9951145B2 (en) 2012-11-27 2018-04-24 Ajou University Industry—Academic Cooperation Foundation CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
WO2014124326A1 (en) * 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
CA2922979A1 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CA2967426A1 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US20160176969A1 (en) * 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
RU2022104399A (ru) * 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек

Also Published As

Publication number Publication date
JP2021506310A (ja) 2021-02-22
JP2023139025A (ja) 2023-10-03
EP3728328A1 (en) 2020-10-28
WO2019122409A1 (en) 2019-06-27
US20190218310A1 (en) 2019-07-18
CN111448217A (zh) 2020-07-24
AU2018387829A1 (en) 2020-05-07
CA3079793A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
ZA202203250B (en) Cd3 binding antibodies
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL263840A (he) נוגדנים קושרי cd3
IL275483A (he) מוליקולות קושרות אנטיגן בי-ספציפיות
IL268517A (he) נוגדנים אנטי-tigit
IL268620A (he) נוגדנים נגד lag3
IL272227A (he) נוגדני anti-tigit
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
ZA201906358B (en) Improved antigen binding receptors
IL279235A (he) נוגדנים ביספציפיים dll3-cd3
GB201709808D0 (en) Antibodies
HUE059237T2 (hu) GARP-TGF-béta antitestek
GB201710838D0 (en) Bispecific antibodies
IL271128A (he) נוגדני נגד-3cd חדשים
ZA202004908B (en) Bispecific antibody
GB201720970D0 (en) Antibodies
IL269577B (he) נוגדנים ביספציפיים אנטי–pd–l1–אנטי–tim–3
IL282355A (he) נוגדנים ביספציפיים מכוונים לאקסוזומים
IL271067A (he) נוגדנים אנטי- trkb
IL274676A (he) הרכב לקשירת אנטיגן דו-ספציפי
GB201711785D0 (en) Antibodies
GB201715149D0 (en) IL-ß binding antibody
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies